News | Antiplatelet and Anticoagulation Therapies | June 27, 2018

AFib Patients Want More Information About Anticoagulation Reversal

Majority of patients in five-country poll considered it important to know about a medication which could stop the blood thinning effects of their medication if needed

AFib Patients Want More Information About Anticoagulation Reversal

June 27, 2018 — Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance of patient-physician discussion around the reversal of blood thinning (anticoagulant) treatments in potential emergency situations.

AF is the most common cardiac rhythm disorder worldwide1 and increases the risk of stroke five-fold.2 Anticoagulants reduce the blood’s ability to form clots and reduce the risk of stroke. However, in emergency situations, such as when rapid initiation of surgery is required, or in the case of a life-threatening bleed, quick reversal of anticoagulation may be required.

AF patients in the survey were very aware of potential complications related to their treatment in the event of an emergency (89 percent).3 However, more than half (51 percent) could not recall having a discussion with their doctor about stopping their blood thinning medication in an emergency. Yet 78 percent would prefer such information about reversibility to come directly from their treating physician compared to other possible sources.

“First of all, it is important that AF patients understand the importance of anticoagulation and its role in preventing strokes. However, it is clear from these survey results that knowing more about how anticoagulant medication could be stopped in the event of an emergency is also very important to patients. This highlights the need for physicians to address this topic in ongoing discussions with their AF patients,” commented Prof. Harald Darius, head of the department of cardiology, angiology, nephrology and intensive-care medicine at the Vivantes Neukoelln Medical Center, Berlin in Germany.

Highlights from the survey include:

  • Sixty-four percent of patients surveyed said it would give them ‘peace of mind, allowing them to worry less about their health’ if they knew that the effects of their blood thinning medication could be reversed in case of an emergency;
  • Nearly 1 in 4 (23 percent) indicated they would feel ‘confident’ if they knew that there was a medication available that could stop the blood thinning effects of their anticoagulant treatment in case of an emergency; and
  • Thirty-one percent said it would allow them to live a more active lifestyle.

An online poll was conducted by Branding Science, an independent market research consultancy, on behalf of Boehringer Ingelheim. The poll was conducted in five countries between October and November 2017 amongst patients diagnosed with AF who have been prescribed a blood thinning (anticoagulation) therapy for stroke prevention.

The poll sought to evaluate patient attitudes towards anticoagulation and potential reversal in an emergency. It was conducted among 902 AF patients living in Belgium, Germany, Italy, Russia and the United States. The respondents were 63 percent male and 37 percent female, with 39 percent of the patients between 56 and 70 years of age being on blood thinning treatment because of AF for 6.8 years on average.

View the full survey results here.

For more information: www.boehringer-ingelheim.com

References

1. Lloyd-Jones DM, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6.

2. Camm AJ, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart. 2012; 33:2719-2747

3. Research carried out by Branding Science, Data on file

Related Content

Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional bleeding, a new...
Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Overlay Init